Advertisement
Advertisement
STVN
Stevanato Group S.p.A.
22.70
USDSponsored
+0.43
+1.93%
Aug 25, 15:59 UTC -4
Closed
After-Market
22.70
0.00
+0.02%
STVN Earnings Reports
Positive Surprise Ratio
STVN beat 14 of 21 last estimates.
67%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$328.45M
/$0.15
Implied change from Q2 26 (Revenue/ EPS)
+8.76%
/+7.14%
Implied change from Q3 25 (Revenue/ EPS)
+8.33%
/+7.14%
Stevanato Group S.p.A. earnings per share and revenue
On Aug 04, 2026, STVN reported earnings of 0.14 USD per share (EPS) for Q2 26, beating the estimate of 0.13 USD, resulting in a 7.61% surprise. Revenue reached 302.00 million, compared to an expected 304.37 million, with a -0.78% difference. The market reacted with a -4.57% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 0.15 USD, with revenue projected to reach 328.45 million USD, implying an increase of 7.14% EPS, and increase of 8.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Stevanato Group S.p.A.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Stevanato Group S.p.A. reported EPS of $0.14, beating estimates by 7.61%, and revenue of $302.00M, -0.78% below expectations.
How did the market react to Stevanato Group S.p.A.'s Q2 2026 earnings?
The stock price moved down -4.57%, changed from $20.59 before the earnings release to $19.65 the day after.
When is Stevanato Group S.p.A. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Stevanato Group S.p.A.'s next earnings report?
Based on 10
analysts, Stevanato Group S.p.A. is expected to report EPS of $0.15 and revenue of $328.45M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement